Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

A1 Journal article (refereed)

Internal Authors/Editors

Publication Details

List of Authors: Valta MP, Zhao HJ, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimaki J, Harkonen P, Coleman I, Nelson PS, Corey E, Peehl DM
Publisher: SPRINGER
Publication year: 2016
Journal: Clinical and Experimental Metastasis
Journal acronym: CLIN EXP METASTAS
Volume number: 33
Issue number: 4
Start page: 325
End page: 337
Number of pages: 13
ISSN: 0262-0898
eISSN: 1573-7276


LuCaP serially transplantable patient-derived xenografts (PDXs) are valuable preclinical models of locally advanced or metastatic prostate cancer. Using spheroid culture methodology, we recently established cell lines from several LuCaP PDXs. Here, we characterized in depth the features of xenografts derived from LuCaP 136 spheroid cultures and found faithful retention of the phenotype of the original PDX. In vitro culture enabled luciferase transfection into LuCaP 136 spheroids, facilitating in vivo imaging. We showed that LuCaP 136 spheroids formed intratibial, orthotopic, and subcutaneous tumors when re-introduced into mice. Intratibial tumors responded to castration and were highly osteosclerotic. LuCaP 136 is a realistic in vitro-in vivo preclinical model of a subtype of bone metastatic prostate cancer.


Androgen-dependence, Bone metastasis, Osteosclerosis

Last updated on 2019-17-10 at 03:14